ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0728

Glomerular Proteomic Signature in ANCA-associated Glomerulonephritis

Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0422

Greater Use of Assisted Reproductive Techniques but Comparable Obstetric Morbidity in a Population of Women with Spondyloarthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0605

Guselkumab Binding to CD64+ IL-23–Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling

SpA Including PsA – Treatment Poster I

10:30AM-12:30AM: Abstract Number: PP12

Healing Together: The Role of Black, Indigenous and People of Color (BIPOC) -Only Chronic Illness Spaces in Comprehensive Care

Patient Perspectives Poster

10:30AM-12:30PM: Abstract Number: 0522

Hematological Impact Assessment of Tofacitinib, Baricitinib, and Upadacitinib in Rheumatoid Arthritis Treatment

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0617

Hereditary C1q Deficiency Is Associated with Type 1 Interferon-pathway Activation and a High Risk of Central Nervous System Inflammation

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0546

Hiding in Plain Sight: The Impact of Implementing an Automated Inflammatory Back Pain Screening Tool on the Identification of Axial Spondyloarthritis in a Community Rheumatology Practice

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0257

High Prevalence of Strongyloides Antibodies in Patients at Risk for Dissemination. A Call for Action

Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: Abstract Number: 0710

High S100A4 Levels Associate with Inflammation and Vasculopathy in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0743

Higher Baseline FDG Musculoskeletal Uptake at PET/CT Is Associated with a Higher Remission Rate in Polymyalgia Rheumatica: A Retrospective 3-year Observational Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0423

Higher Risk of Preterm Delivery in Women with Rheumatoid Arthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0389

Histopathological Features of Liver Tissue Biopsies in SJIA Patients with and Without Clinical Macrophage Activation Syndrome

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0224

How Accurate Are Assessments by Local Radiologists of Sacroiliac Joint MRIs in Axial Spondyloarthritis and Psoriatic Arthritis in Routine Clinical Practice?- Evidence from 873 Patients in Five European Countries

Imaging of Rheumatic Diseases Poster I: Inflammatory Arthritis

10:30AM-12:30AM: Abstract Number: PP03

How Completing a Systematic Literature Review Improved How I Research My Own Rheumatoid Arthritis and Comorbidities

Patient Perspectives Poster

10:30AM-12:30PM: Abstract Number: 0374

How Do Patient Decision Aids Enable Purposeful Shared Decision-Making in Rheumatology? An Integrative Review

Patient Outcomes, Preferences, & Attitudes Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].